Phase I/II Study of Brentuximab Vedotin in Pediatric Patients with Relapsed or Refractory HL or Systemic Anaplastic Large Cell Lymphoma


Phase I/II Study of Brentuximab Vedotin in Pediatric Patients with Relapsed or Refractory HL or Systemic Anaplastic Large Cell Lymphoma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Christopher Flowers, MD, MS (2/24/14)
Locatelli F et al. Phase 1/2 study of brentuximab vedotin in pediatric patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL): Preliminary Phase 2 data for brentuximab vedotin 1.8 mg/kg in the HL study arm. Proc ASH 2013;Abstract 4378.

Dr Flowers is Associate Professor of Hematology and Medical Oncology at Emory School of Medicine Winship Cancer Institute in Atlanta, Georgia.